Patents by Inventor Franco Cavaleri

Franco Cavaleri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240358673
    Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids, gallates, and (optionally) one or more ketones are disclosed. The compositions include one or more short chain fatty acids (such as butyric acid, butyrate salts, propionic acid, propionate salts, acetic acid, or acetate salts); epigallocatechin gallate (EGCG); and, optionally, one or more beta-hydroxybutyrate salts. The compositions and methods are useful for inducing weight loss, ketosis, brown adipose fat cell differentiation, and/or beta-oxidative activity in a subject.
    Type: Application
    Filed: October 6, 2023
    Publication date: October 31, 2024
    Inventor: Franco Cavaleri
  • Patent number: 12090122
    Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: September 17, 2024
    Inventor: Franco Cavaleri
  • Publication number: 20240238219
    Abstract: Compositions that include concentrated amounts of curcumin II and/or curcumin III, along with concentrated amounts of turmerones, are disclosed. The compositions may be useful for increasing LDL receptor levels in a plurality of cells. In addition, the compositions may be useful for decreasing MSK1 levels in a plurality of cells. The compositions may also be used to increase expression of brain derived neurotrophic factor (BDNF) in a plurality of cells.
    Type: Application
    Filed: March 28, 2024
    Publication date: July 18, 2024
    Inventor: Franco Cavaleri
  • Publication number: 20240156771
    Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids, chlorogenic acid, and, optionally, ketones are disclosed. The compositions include one or more short chain fatty acids (such as butyric acid, butyrate salts, propionic acid, propionate salts, acetic acid, or acetate salts); chlorogenic acid; and, optionally, one or more beta-hydroxybutyrate salts. The compositions and methods are useful for inducing ketosis and/or beta-oxidative activity in a subject. In addition, compositions that include concentrated forms of, and methods of using, chlorogenic acid (alone or in combination with short chain fatty acids and ketones) to induce ketogenesis in a subject are disclosed.
    Type: Application
    Filed: September 26, 2023
    Publication date: May 16, 2024
    Inventor: Franco Cavaleri
  • Publication number: 20240123016
    Abstract: Compositions that contain enriched amounts of Withanolides are provided. Such compositions will include natural extracts of Ashwagandha (Withania somnifera), including whole plant extracts and/or root extracts, which have been supplemented with or contain elevated amounts of Withanolide A, Withanolide B, Withanolide D, Withaferin A, Withanoside IV, and/or Withanoside V. Methods for modulating GPX1, Nrf2, HO1, mTOR, TERT, ?-Catenin, and/or NF-?B using such Withanolide-enriched compositions are also disclosed, as well as using such Withanolide-enriched compositions to stimulate hair growth.
    Type: Application
    Filed: December 23, 2023
    Publication date: April 18, 2024
    Inventor: Franco Cavaleri
  • Publication number: 20240099990
    Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.
    Type: Application
    Filed: December 7, 2023
    Publication date: March 28, 2024
    Inventor: Franco Cavaleri
  • Publication number: 20240082339
    Abstract: Compositions that contain enriched amounts of Withanolides are provided. Such compositions will include, consist essentially of, or consist entirely of natural extracts of Ashwagandha (Withania somnifera), including whole plant extracts and/or root extracts, which have been supplemented with additional amounts of Withanolide A, Withanolide B, Withanolide D, Withaferin A, Withanoside IV, and/or Withanoside V. The additional amounts of such Withanolides that are added to the Ashwagandha extracts may be naturally occurring isolates or synthetic versions of such Withanolides, such that the total/final Withanolide concentration is at least ten (10%)(w/w)—but may include even higher concentrations of such Withanolides. Methods for modulating GPX1, Nrf2, HO1, mTOR, TERT, ?-Catenin, and/or NF-KB using such Withanolide-enriched compositions are also disclosed.
    Type: Application
    Filed: January 13, 2022
    Publication date: March 14, 2024
    Inventor: Franco Cavaleri
  • Patent number: 11432573
    Abstract: Natural sweetener compositions are disclosed, which generally include various combinations of steviol glycosides extracted from a Stevia rebaudiana plant; Siraitia grosvenorii (Monk Fruit) plant extract (including mogrosides extracted from such plant species); and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally further include gymnemic acid (such as an extract of a Gymnemic sylvestre herb that includes 25%-75% gymnemic acid). The natural sweetener compositions may consist essentially of those two, three, or four components—or may be included in beverages, beverage powders, and foods.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 6, 2022
    Inventor: Franco Cavaleri
  • Publication number: 20210220302
    Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Inventor: Franco Cavaleri
  • Publication number: 20210161834
    Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Inventor: Franco Cavaleri
  • Patent number: 10987326
    Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: April 27, 2021
    Inventor: Franco Cavaleri
  • Patent number: 10945970
    Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: March 16, 2021
    Inventor: Franco Cavaleri
  • Publication number: 20200229475
    Abstract: Natural sweetener compositions are disclosed, which generally include steviol glycosides extracted from a Stevia rebaudiana plant and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally further include gymnemic acid (such as an extract of a Gymnemic sylvestre herb that includes 25%-75% gymnemic acid). The natural sweetener compositions may consist essentially of those two or three components—or may be included in beverages, beverage powders, and foods.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 23, 2020
    Inventor: Franco Cavaleri
  • Publication number: 20200154748
    Abstract: Natural sweetener compositions are disclosed, which generally include various combinations of steviol glycosides extracted from a Stevia rebaudiana plant; Siraitia grosvenorii (Monk Fruit) plant extract (including mogrosides extracted from such plant species); and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally further include gymnemic acid (such as an extract of a Gymnemic sylvestre herb that includes 25%-75% gymnemic acid). The natural sweetener compositions may consist essentially of those two, three, or four components—or may be included in beverages, beverage powders, and foods.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Inventor: Franco Cavaleri
  • Publication number: 20190380982
    Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.
    Type: Application
    Filed: July 1, 2019
    Publication date: December 19, 2019
    Inventor: Franco Cavaleri
  • Patent number: 10376482
    Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 13, 2019
    Inventor: Franco Cavaleri
  • Publication number: 20180360774
    Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 20, 2018
    Inventor: Franco Cavaleri
  • Publication number: 20180353443
    Abstract: Methods for modulating miRNA148a levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III in order to increase miRNA148a levels, or providing to the cells a curcumin II-enriched composition in order to reduce miRNA148a levels. In addition, compositions for elevating miRNA148a levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 5% curcumin III and a pharmaceutically-acceptable solvent, filler, or carrier. Similarly, compositions for reducing miRNA148a levels in a plurality of cells are disclosed, which include a curcumin II-enriched composition and a pharmaceutically-acceptable solvent, filler, or carrier.
    Type: Application
    Filed: May 18, 2018
    Publication date: December 13, 2018
    Inventor: Franco Cavaleri
  • Publication number: 20170290785
    Abstract: Methods for modulating miRNA148a levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III, in order to increase miRNA148a levels. In addition, compositions for elevating miRNA148a levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 5% curcumin III and a pharmaceutically-acceptable solvent, filler, or carrier.
    Type: Application
    Filed: September 7, 2016
    Publication date: October 12, 2017
    Inventor: Franco Cavaleri
  • Publication number: 20170290784
    Abstract: Methods for reducing MSK1 levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III. Methods for inhibiting MSK1 serine376 phosphorylation in a plurality of cells are also disclosed, which include providing to the cells a curcumin composition that is at least 5% curcumin III. In addition, methods for ameliorating inflammation in a subject are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. Still further, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. In addition, compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier.
    Type: Application
    Filed: August 14, 2016
    Publication date: October 12, 2017
    Inventor: Franco Cavaleri